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Leuprolide acetate is usually used in the treatment of advanced prostate cancer. The adverse events
associated with administration of leuprolide acetate include fatigue, hot ﬂashes, loss of libido, impotence,
and depression. These side effects can be treated conservatively. Acute manic and psychiatric symptoms
following leuprolide acetate injection are very rare. Few case reports have been published documenting
these symptoms. Here, we describe the case of a 62-year-old male with metastatic prostate cancer, who
developed acute manic and psychiatric symptoms 2 months after subcutaneous leuprolide acetate
injection. These symptoms were relieved after administration of neuroleptic drugs, such as risperidone.
Administration of leuprolide acetate was eventually stopped. The exact mechanism causing the manic
and psychiatric adverse events is unclear. Some experts have theorized that estrogen withdrawal
following leuprolide acetate therapy may induce psychiatric symptoms. Manic episodes may arise from a
deﬁcit in central serotonergic neurotransmission. Based on these hypotheses, risperidone, lithium, and
some anticonvulsants, such as divalproex sodium and carbamazepine, have been used effectively in the
treatment and prophylaxis of manic episodes. Although psychiatric adverse events are rare following
administration of leuprolide acetate, clinicians should be aware of the possibility.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Leuprolide acetate is a synthetic nonpeptide analog of naturally
occurring gonadotropin-releasing hormone. Leuprolide acetate
overstimulates the body’s own production of human luteinizing
hormone-releasing hormone, which then shuts down. Through this
process, leuprolide acetate reduces the amount of testosterone in
men and estrogen in women.
Leuprolide acetate is usually used in the treatment of advanced
prostate cancer in men and symptoms of endometriosis in women.
It is also used to treat precocious puberty in both male and female
children. Fatigue, hot ﬂashes, loss of libido, and impotence are the
most common adverse effects, all of which can be treated conser-
vatively. Adverse events affecting the central nervous system, suchNational Taiwan University
rsity, Number 7, Chung Shan
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ciation. Published by Elsevier Taiwas anxiety, blurred vision, lethargy, mood swings, insomnia, and
depression have been reported in <5% of patients treated with
leuprolide acetate. Acute manic and psychiatric symptoms are
rarely reported as a result of leuprolide acetate injection. Only a few
case reports have been presented in themedical literature. Here, we
report the case of a 62-year-old male with metastatic prostate
cancer, in whom acute manic and psychiatric symptoms developed
2 months after subcutaneous leuprolide acetate injection.
2. Case report
We describe the case of a 62-year-old man without previous
psychiatric history or mood disorder diagnosed in October 2010
with prostate cancer, which metastasized to the bone. Androgen
deprivation therapy was administered monthly in the form of
leuprolide acetate (3.75 mg) subcutaneous injections. After the
second dosage, the patient gradually became increasingly elated,
expressive, hyperactive, and increasingly talkative about his work
and future plans. A decreased need for sleep also developed.
The patient’s medical history revealed no drug abuse or alcoholan LLC. Open access under CC BY-NC-ND license.
Y.-H. Pong et al. / Urological Science 25 (2014) 22e24 23consumption until that time. Laboratory examinations showed
normal thyroid and adrenal function. A toxicology screen was
negative for illegal substances. However, impaired liver function
was revealed, and may have been caused by hepatitis C. Brain
magnetic resonance imaging demonstrated atrophy, but no obvious
brain or skull metastases. Electroencephalography revealed no
overt abnormalities; however, hypersomnolent tendencies were
noted.
Upon admission, oral neuroleptic drug treatment was started
(risperidone and haloperidol) under the diagnosis of substance-
induced acute manic episode, according to the criteria of the
fourth edition of the Diagnostic and Statistical Manual of Mental
Disorders. Manic symptoms subsided 1 week after administration
of this treatment. One month after discharge, the patient’s
overall good condition allowed discontinuation of leuprolide ace-
tate. Follow-up revealed no psychiatric symptoms requiring
hospitalization. Risperidone for controlling symptoms was also
discontinued.
3. Discussion
Prostate cancer is very prevalent in geriatric populations. Since
1995, approximately 2,600,000 men in the United States have been
diagnosed with prostate cancer, and nearly 375,000 men have lost
their lives to this disease.1 However, mortality rates due to prostate
cancer appear to be declining; 34,475 men died in 1995 from the
disease compared with an estimated 30,350 in 2005. This is due to
improvements in prostate cancer treatments. Androgen depriva-
tion therapy, such as leuprolide acetate, goserelin acetate, and
triptorelin acetate are commonly used in the treatment of advanced
prostate cancer. Adverse events, such as fatigue, hot ﬂashes,
depression, and loss of libido are common and can be treated
conservatively. However, acute manic and psychiatric symptoms
following leuprolide acetate treatment are very rare. Only a few
case reports are available in the medical literature; most of these
cases were females in whom leuprolide acetate treatment was
administered for endometriosis.
Warnock and Bundren 2 published the ﬁrst two cases of leu-
prolide acetate-induced mania. The ﬁrst case was a 37-year-old
female with a history of endometriosis in whom leuprolide acetate
was injected for treatment of endometriosis. After the second in-
jection, she presented with decreased motivation, distractibility,
passive suicidal ideation, and extreme irritability. These symptoms
improved after discontinuation of the injections and without
additional medication for manic symptoms. The other case was a
22-year-old female with a history of endometriosis and fallopian
tube occlusion, in whom leuprolide acetate was administered. Two
weeks after injection, crying spells, decreased sleep, and irritability
developed. These symptoms markedly improved after 6 weeks of
administration of the antipsychotic drug sertraline.
Rachman et al3 reported a 28-year-old female with a 6-year
history of endometriosis in whom a series of leuprolide acetate
injections was administered. After the ﬁfth leuprolide acetate in-
jection, she presented with irritability, argumentativeness,
distractibility, and a decreased need for sleep. She was diagnosed
with bipolar disorder (manic status). Treatment with lithium car-
bonate induced calmness and reduced impulsiveness.
Although female cases have been reported since 1997, the ﬁrst
male patient with these symptoms was only reported in 2010 by
Chavez and Reilly.4 Leuprolide acetate injection treatment was
administered in a 65-year-old male with a history of metastatic
prostate cancer. Two months after the ﬁrst injection, the patient
showed the following peculiarities: extreme agitation, shouting of
profanities, decreased sleep, an increasingly talkative nature, and
pressured speech. A review of past medical and family historyshowed no psychiatric illnesses. The behavior deviated markedly
from the norm. Symptoms improved on the 9th day after initiation
of olanzapine treatment. After discharge, olanzapine was dis-
continued; 1 month later, the patient was doing well, with no
psychiatric symptoms.
The exact mechanism underlying the development of psychi-
atric symptoms after administration of leuprolide acetate remains
unclear. One hypothesis is related to the mood stabilizing effects of
estrogen. Abrupt pharmacological castration and subsequent
decreased serum estrogen levels may be related to the develop-
ment of the acute psychosis associated with leuprolide acetate in-
jection in the cases described here. Rachman et al3 performed
animal experiments in female rats that had received an ovariec-
tomy. Signiﬁcant behavioral changes and hyperactivity were
observed postoperatively. Another estrogen protection hypothesis
was put forward by Riecher-Rossler in 2002, in which estrogen
exerted a protective effect on psychotic symptoms in susceptible
patients.5 Huber et al also found lower levels of total testosterone,
free testosterone, and estradiol in men with acute psychosis
compared with those in the control group.6 Another hypothesis
regarding the manic episodes, postulated that a deﬁcit in central
serotonergic neurotransmission permits the expression of sub-
stances that cause manic episodes.7
Based on the results of these studies, measurement of testos-
terone and estradiol levels should be performed in cases like the
one reported here. Unfortunately, these measurements were not
performed in our case. Clinicians should be aware of the beneﬁt of
these tests. Future studies may reveal the exact mechanism un-
derlying manic episodes associated with administration of leu-
prolide acetate.
The management of leuprolide acetate-induced psychosis cases
is not identical. In the case reported here, administration of leu-
prolide acetate was discontinued, after which the patient was
observed until recovery. If symptoms persist or progress, neuro-
leptic drugs such as risperidone and haloperidol may be consid-
ered. Some clinicians and studies have claimed that lithium,
anticonvulsants such as divalproex sodium and carbamazepine are
effective in the treatment and prophylaxis of manic episodes,
because they are involved in enhancement of 5-HT function in the
central nervous system.8
In the case reported here, no prior psychiatric history or relevant
endocrine problems were evident. Thus, the manic behavior and
anxiety symptoms were considered to be manifestations of a leu-
prolide acetate-induced psychiatric disorder. According to a study
created by eHealthMe based on 5886 reports from the Food and
Drug Administration and the user community, goserelin acetate-
induced manic episodes are also possible; these are still, howev-
er, very rare.9
To our knowledge, this is only the second case report of a male
patient, with no prior psychiatric history, inwhom acute manic and
psychiatric symptoms developed after leuprolide acetate injection.
We report this rare case of adverse events occurring following
leuprolide acetate administration for fellow clinicians, who should
be aware of this rare psychiatric side effect.Conﬂicts of interest statement
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